Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: A multicenter retrospective study of inpatients, 2009-2011  by Magee, Glenn et al.
lable at ScienceDirect
American Journal of Infection Control 43 (2015) 1148-53Contents lists avaiAmerican Journal of Infection Control
journal homepage: www.aj ic journal .org
American Journal of 
Infection ControlMajor articleImpact of Clostridium difﬁcile-associated diarrhea on acute care
length of stay, hospital costs, and readmission: A multicenter
retrospective study of inpatients, 2009-2011
Glenn Magee MBA a,*, Marcie E. Strauss MPH b,1, Sheila M. Thomas PharmDb,2,
Harold Brown MHA, MBA a, Dorothy Baumer MS a, Kelly C. Broderick PharmD c
a Premier Research Services, Charlotte, NC
bHealth Economics and Outcomes Research, Optimer Pharmaceuticals, Jersey City, NJ






Readmission* Address correspondence to Glenn Magee, MBA,
Place, Charlotte, NC 28277.
E-mail address: glenn_magee@premierinc.com (G.
Funding/Support: Funding for the study was pro
Kenilworth, NJ.
Disclaimer: The funder worked with investigator
and analyze data, and interpret the results. All authors
the report for publication, and all drafts of the repor
responding author with input from the coauthors an
professional medical writer, funded by the sponsor.
Conﬂicts of interest: Magee, Brown, and Baumer p
by Optimer Pharmaceuticals, Jersey City, NJ, at the tim
Thomas and Strauss were employed by Optimer Pha
manuscript was being developed. Strauss was issu
Options as part of the acquisition agreement betwee
maceuticals, Lexington, MA, now Merck & Co., Inc., Ke
employee of Merck & Co., Inc.
1 Strauss is now at 20 Herbert Ave, White Plains, N
2 Thomas is now at 1300 Steamboat Springs Ct, Bla
0196-6553/Copyright 2015 by the Association for Pro
CC BY-NC-ND license (http://creativecommons.org/lic
http://dx.doi.org/10.1016/j.ajic.2015.06.004Background: The recent epidemiologic changes of Clostridium difﬁcile-associated diarrhea (CDAD) have
resulted in substantial economic burden to U.S. acute care hospitals. Past studies evaluating CDAD-
attributable costs have been geographically and demographically limited. Here, we describe CDAD-
attributable burden in inpatients, overall, and in vulnerable subpopulations from the Premier hospital
database, a large, diverse cohort with a wide range of high-risk subgroups.
Methods: Discharges from the Premier database were retrospectively analyzed to assess length of stay
(LOS), total inpatient costs, readmission, and inpatient mortality.
Results: Patients with CDAD had signiﬁcantly worse outcomes than matched controls in terms of total
LOS, rates of intensive care unit (ICU) admission, and inpatient mortality. After adjustment for risk
factors, patients with CDAD had increased odds of inpatient mortality, total and ICU LOS, costs, and odds
of 30-, 60- and 90-day all-cause readmission versus non-CDAD patients. CDAD-attributable costs were
higher in all studied vulnerable subpopulations, which also had increased odds of 30-, 60- and 90-day
all-cause readmission than those without CDAD.
Conclusion: Given the signiﬁcant economic impact CDAD has on hospitals, prevention of initial episodes
and targeted therapy to prevent recurrences in vulnerable patients are essential to decrease the overall
burden to hospitals.
Copyright  2015 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).13034 Ballantyne Corporate
Magee).
vided by Merck & Co., Inc.,
s to design the study, collect
made the decision to submit
t were prepared by the cor-
d editorial assistance from a
erformed research contracted
e the study was conducted.
rmaceuticals at the time this
ed Contingent Value Rights
n Optimer and Cubist Phar-
nilworth, NJ. Broderick is an
Y 10606.
cklick, OH 43004.
fessionals in Infection Control and
enses/by-nc-nd/4.0/).In the last 15 years, the epidemiology of Clostridium difﬁcile-
associated diarrhea (CDAD) has changed, resulting in increased
incidence and severity.1-3 Between 2000 and 2009, C difﬁcile
infection hospitalizations increased by 237% in the United States,4
with nearly 1% of all hospitalizations involving CDAD in 2009.2
Additionally, nearly 250,000 people require hospital care for
CDAD each year.5 Despite current therapies, CDAD-related
morbidity and mortality rates remain high,6 with worse out-
comes and higher acute care costs than in patients without CDAD.7,8
This is particularly true in patients with risk factors, including renal
disease, malignant neoplasms, immunocompromising conditions,
inﬂammatory bowel disease (IBD), or concomitant antibiotic use,
where CDAD is associated with substantially increased economic
burden.9,10
Studies evaluating the U.S. health care costs attributable to CDAD
have been limited to individual hospitals, speciﬁc populations, and
small geographic areas.11,12 One recent review noted that mostEpidemiology, Inc. Published by Elsevier Inc. This is an open access article under the
G. Magee et al. / American Journal of Infection Control 43 (2015) 1148-53 1149previous studies included small sample sizes or inadequate control
of confounders, such as comorbidities and increased age and illness
acuity, factors that are more likely in patients with CDAD than in
those without, and that cost differences may vary by region.11
Another found that attributable outcomes (costs and length of
stay [LOS]) were erratic among studies and not consistently
reported, making it difﬁcult to draw meaningful conclusions.12
The current study was designed to address the shortcomings of
earlier assessments of CDAD-related burden on U.S. acute care
hospitals. The primary strengths of the Premier hospital database
include geographic diversity and its representative sampling of
teaching and nonteaching hospitals. Additionally, its large size is
likely adequate to provide meaningful conclusions regarding
vulnerable subgroups. Our primary aimwas to describe the burden




This retrospective, observational study used data from the Pre-
mier hospital database, a deidentiﬁed patient database containing a
complete census of inpatients from geographically diverse hospi-
tals, with patient demographic information, hospital characteris-
tics, and all discharge ICD-9-CM diagnoses and procedure codes.
Date-stamped information was available for all billed services,
including medications and diagnostic and therapeutic services in
patient daily service records. The database is compliant with the
Health Insurance Portability and Accountability Act of 1996.
Patient selection
The inpatient population with CDAD was identiﬁed using the
ﬁrst inpatient discharge (index discharge) between January 1, 2009,
and December 31, 2011, in which the patient met the following
criteria: aged 18 years at discharge; principal or secondary
discharge diagnosis of ICD-9-CM 008.45 (intestinal infection
caused by C difﬁcile); received ﬁdaxomicin, metronidazole, or
vancomycin during index hospitalization; and no previous hospital
admission 90 days before index admission.
The non-CDAD control population was selected using the ﬁrst
inpatient discharge for patients who met the following criteria:
index discharge between January 1, 2009, and December 31, 2011;
aged 18 years at discharge; no previous hospital admission
90 days before index admission; and no record of ICD-9-CM code
008.45.
Patients without CDADwerematched 1:1 to patients with CDAD
in a 2-step process. First, patients from both cohorts were catego-
rized by Medicare severity diagnosis-related group. Within each
group, individuals were matched using the Mahalanobis caliper
method for propensity score matching.13 All propensity score
logistic models used the same covariates: patient demographics
(age, sex, race, admission source, admit type, and discharge year)
and hospital characteristics (geographic region, teaching status,
urban-rural status, and number of beds). All models were assessed
for goodness-of-ﬁt using the concordance c statistic. All matched
patients were then aggregated, and the data were reviewed for
outliers in LOS and total costs, which were removed from the
analysis ﬁle, from which all analyses were conducted.
Subgroup analysis
Several subgroupswere identiﬁed from thematched analysis ﬁle,
most of which were identiﬁed by ICD-9-CM codes. These includedpatients with renal impairment (ICD-9-CM codes: 403.01, 403.11,
403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 582.x, 583.0-
583.7, 585.x, 586.x, 588.0, V42.0, V45.1, V56.x), malignant neoplasms
(140.x-172.x,174.x-195.8, 200.x-208.x, 238.6), and IBD (556.x, 555.x).
The exceptions were patients with immunocompromised status
(identiﬁed as those exposed to selected alkylating agents, platinum
compounds, antimetabolites, antimitotics, epipodophyllotoxins,
pegaspargase, asparaginase, DNA topoisomerase inhibitors, biologic
response modiﬁers, monoclonal antibodies, bortezomib, and tyro-
sine kinase inhibitors) and patients with concomitant antibiotic
usage (identiﬁed as those exposed to carbapenems, cephalosporins,
penicillins, aminoglycosides, tetracyclines, macrolides, ﬂuoroqui-
nolones, and b-lactams). The subgroupswere notmutually exclusive,
and patients could be included in >1 subgroup.
Outcomes
The impact of CDAD was evaluated by assessing the following
outcomes: index hospitalization LOS; total inpatient costs; re-
admission within 30, 60, and 90 days of index discharge; and
inpatient mortality. Costs were reported by hospitals as patient
care costs and were not based on charges or cost-to-charge ratios.
Readmission rates reﬂected all-cause readmission to the same
hospital within the speciﬁed time periods for patients discharged
alive from the index hospitalization.
Statistical analysis
Unadjusted baseline characteristics for the matched CDAD and
non-CDAD groups were evaluated. Categorical variables were
compared using c2 test, and continuous variables were evaluated
using Student t test. Risk-adjusted models were developed for the
outcomes of interest. Categorical outcomes were modeled using
logistic regression, and continuous variables were modeled using
generalized linearmodels. Because of the skewed distribution of the
continuous outcomes (LOS and costs), linear models used a log link
with a gamma distribution. Outputs were exponentiated to present
results in the original unit of measurement. Covariates used in all
models included age, sex, race, admission source, admission type,
intensive care unit (ICU) admission, Charlson comorbidity index
score, geographic region, teaching status, urban-rural status, and
number of beds. All models were assessed for goodness-of-ﬁt. The P
values <.05 were considered statistically signiﬁcant. All analyses
were conducted using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
After matching, there were 171,586 eligible discharges (85,793
per cohort). There were 2,443 (1.4%) extreme outliers with total
costs <$1,000 or >$200,000 or LOS >100 days (CDAD cohort, 1,568
[1.8%]; non-CDAD, 875 [1.0%]). The ﬁnal analysis dataset included
169,143 discharges (84,225 CDAD; 84,918 non-CDAD).
Patient and hospital characteristics are presented in Table 1. The
matching schemewas effective in balancing several characteristics;
however, signiﬁcant differences still existed in part because of the
very large patient population. The CDAD cohort had a greater
number of patients who were white and who were admitted from
skilled nursing facilities (SNFs) (both P < .01). Patients with CDAD
also had a signiﬁcantly elevated mean Charlson comorbidity index
score (P < .01), indicating greater underlying comorbidity. Hospital
characteristics were well balanced.
Table 2 presents select subgroup demographics. Although the
mean age was slightly lower for patients with CDAD in the renal
impairment and neoplasm subgroups and slightly higher for
patients with CDAD in the IBD, immunocompromised, and
Table 2
Select demographics by subgroup
Description CDAD Non-CDAD P value
Total eligible discharges
Renal impairment 40,232 (100.0) 32,731 (100.0)
Neoplasm 12,334 (100.0) 10,834 (100.0)
Immunocompromised 4,632 (100.0) 3,372 (100.0)
Inﬂammatory bowel
disease
2,972 (100.0) 1,551 (100.0)
Concomitant antibiotic 55,054 (100.0) 52,524 (100.0)
Age, y
Renal impairment 70.9  15.0 71.3  14.7 <.01
Neoplasm 67.7  14.1 68.6  13.5 <.01
Immunocompromised 61.5  17.2 60.3  16.7 <.01
Inﬂammatory bowel
disease
57.7  20.7 52.8  19.8 <.01
Concomitant antibiotic 68.3  16.7 67.7  16.8 <.01
Female sex
Renal impairment 20,517 (51.0) 16,409 (50.1) .02
Neoplasm 6,019 (48.8) 5,228 (48.3) .42
Immunocompromised 2,321 (50.1) 1,652 (49.0) .32
Inﬂammatory bowel
disease
1,602 (53.9) 854 (55.1) .44
Concomitant antibiotic 30,143 (54.8) 28,602 (54.5) .10
SNF transfer admission source
Renal impairment 3,496 (8.7) 1,229 (3.8) <.01
Neoplasm 521 (4.2) 153 (1.4) <.01
Immunocompromised 226 (4.9) 41 (1.2) <.01
Inﬂammatory bowel
disease
120 (4.0) 13 (0.8) <.01
Concomitant antibiotic 4,463 (8.1) 1,772 (3.4) <.01
SNF discharge status
Renal impairment 13,583 (33.8) 7,345 (22.4) <.01
Neoplasm 2,660 (21.6) 1,421 (13.1) <.01
Immunocompromised 1,107 (23.9) 445 (13.2) <.01
Inﬂammatory bowel
disease
518 (17.4) 118 (7.6) <.01
Concomitant antibiotic 18,394 (33.4) 10,911 (20.8) <.01
Charlson comorbidity index, mean (median)  SD
Renal impairment 3.52 (3.00)  2.39 3.19 (3.00)  2.30 <.01
Neoplasm 4.87 (4.00)  3.51 4.85 (4.00)  3.41 .71
Immunocompromised 4.10 (3.00)  3.43 3.87 (3.00)  3.36 <.01
Inﬂammatory bowel
disease
1.47 (1.00)  2.04 0.86 (0.00)  1.57 <.01
Concomitant antibiotic 2.71 (2.00)  2.47 2.24 (2.00)  2.34 <.01
NOTE. Values are n (%), mean  SD, or as otherwise indicated.
CDAD, Clostridium difﬁcile-associated diarrhea; SNF, skilled nursing facility.
Table 1
Patient and hospital characteristics
Characteristic CDAD Non-CDAD P value*
Patient characteristics
Total discharges 84,225 (100.0) 84,918 (100.0)
Age group, y <.01
18-44 9,114 (10.8) 8,893 (10.5)
45-64 22,848 (27.1) 24,043 (28.3)
65-74 17,430 (20.7) 17,551 (20.7)
75-84 20,808 (24.7) 20,880 (24.6)
85 14,025 (16.7) 13,551 (16.0)
Age, y 67.7  17.2 67.5  17.0 .31
Sex, female 46,429 (55.1) 46,590 (54.9) .10
Race <.01
Black 10,395 (12.3) 10,438 (12.3)
Other 16,280 (19.3) 18,070 (21.3)




28,683 (34.1) 33,063 (38.9)
Home 38,034 (45.2) 38,295 (45.1)
Other 3,487 (4.1) 3,238 (3.8)
Transfer 7,894 (9.4) 7,912 (9.3)
SNF 6,127 (7.3) 2,410 (2.8)
Admission type .82
Elective 9,761 (11.6) 9,754 (11.5)
Emergency 60,421 (71.7) 61,093 (71.9)
Other-unknown 469 (0.6) 469 (0.6)
Urgent 13,574 (16.1) 13,602 (16.0)
Discharge status <.01
Hospice 3,983 (4.7) 2,836 (3.3)
Transferred 7,746 (9.2) 6,930 (8.2)
Expired 8,556 (10.2) 6,743 (7.9)
Home 37,135 (44.1) 51,762 (61.0)
SNF 25,971 (30.8) 15,623 (18.4)




2.57 (2.00)  2.46 2.19 (2.00)  2.33 <.01
Hospital characteristics
Teaching .41
Nonteaching 48,870 (58.0) 49,105 (57.8)
Teaching 35,355 (42.0) 35,813 (42.2)
No. of beds .36
<100 2,607 (3.1) 2,514 (3.0)
100-199 8,264 (9.8) 8,271 (9.7)
200-299 13,804 (16.4) 13,786 (16.2)
300-499 31,045 (36.9) 31,377 (36.9)
500 28,505 (33.8) 28,970 (34.1)
NOTE. Values are n (%), mean  SD, or as otherwise indicated.
CDAD, Clostridium difﬁcile-associated diarrhea; SNF, skilled nursing facility.
*P values indicate differences observed across all groups of each category.
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considered clinically meaningful. Throughout the subgroups,
patients with CDAD had signiﬁcantly higher rates of admission
from and discharge to SNFs (P < .01 for all). Similarly, except for the
neoplasm subgroup (P ¼ .71), patients with CDAD had higher
Charlson comorbidity index scores (P < .01).
Compared with controls, patients with CDAD had signiﬁcantly
worse unadjusted outcomes (Table 3), with longer total LOS and
higher rates of ICU admission and inpatient mortality. Unadjusted
mean patient costs were 46.8% higher and unadjusted 30-day all-
cause readmission rates were 8.4% higher for patients with CDAD
than for patients without CDAD. Similar results were observed for
unadjusted 60- and 90-day all-cause readmission (not presented).
Unadjusted outcomes by subgroup were similar to and direction-
ally the same as outcomes of the total population (Table 3).
After adjusting for risk factors, modeled results continued to
show signiﬁcant differences (Table 4). Patients with CDAD had
increased odds of inpatient mortality, longer total LOS, longer ICU
LOS, increased total patient costs, and increased odds of 30-, 60-,and 90-day all-cause readmission compared with patients without
CDAD (P < .01 for all). These results were statistically signiﬁcant
overall and in the analyzed subgroups (P < .01), with the exception
of odds of inpatient mortality for patients with neoplasms (P ¼ .14)
or immunocompromised status (P ¼ .26). Although directionally
the same, these results were not statistically signiﬁcant.
Costs of care for inpatient discharges attributable to CDAD were
derived by subtracting the adjusted total costs for non-CDAD
patients from those of patients with CDAD. For the eligible popu-
lation, CDAD-attributable costs were $7,286. CDAD-attributable
costs for subgroups are as follows: renal impairment, $8,942;
neoplasm, $6,975; immunocompromised status, $8,692; IBD,
$5,526; and use of concomitant antibiotics, $8,545.
CONCLUSIONS
The burden of CDAD on resource utilization and total cost to
acute care hospitals is signiﬁcant. This study extends previous
research by evaluating a database of all patients treated at 477 U.S.
acute care hospitals during a 3-year period. The incremental costs
of CDAD observed here, both overall and in individual high-risk
subgroups, may provide useful information for cost-beneﬁt ana-
lyses of new treatment regimens for CDAD.
Table 3
Unadjusted outcomes of patients with CDAD versus patients without CDAD
Outcome CDAD Non-CDAD
P value Percentage differenceLength of stay, d Mean  SD Median (IQ range) Mean  SD Median (IQ range)
All eligible 14.4  18.3 10 (5-17) 8.7  15.6 6 (3-10) <.01 65.5
Renal impairment 14.76  12.46 11 (6-19) 9.37  9.26 6 (4-12) <.01 57.5
Neoplasm 15.30  12.67 12 (7-20) 9.97  9.26 7 (4-13) <.01 53.5
Immunocompromised 18.78  14.59 15 (6-19) 12.68  11.72 9 (4-12) <.01 48.1
Inﬂammatory bowel disease 12.45  11.86 8 (4-16) 7.17  7.82 5 (3-8) <.01 73.6
Concomitant antibiotic 15.13  12.67 11 (7-20) 9.44  9.38 6 (4-12) <.01 60.3
ICU admission n % n %
Percentage-point
difference
All eligible 30,942 36.7 26,147 30.8 <.01 5.9
Renal impairment 19,419 48.3 13,398 40.9 <.01 7.3
Neoplasm 4,445 36.0 3,456 31.9 <.01 4.1
Immunocompromised 1,675 36.2 950 28.2 <.01 8.0
Inﬂammatory bowel disease 1,073 36.1 243 15.7 <.01 20.4
Concomitant antibiotic 24,212 44.0 19,003 36.2 <.01 7.8
Inpatient mortality n % n %
Percentage-point
difference
All eligible 8,556 10.2 6,743 7.9 <.01 2.2
Renal impairment 6,550 16.3 4,345 13.3 <.01 3.0
Neoplasm 1,714 13.9 1,345 12.4 <.01 1.5
Immunocompromised 552 11.9 325 9.6 <.01 2.3
Inﬂammatory bowel disease 385 13.0 47 3.0 <.01 9.9
Concomitant antibiotic 6,465 11.7 4,765 9.1 <.01 2.7
Total inpatient costs Mean  SD Median (IQ range) Mean  SD Median (IQ range)
Percentage
difference
All eligible $27,408  $30,664 $16,353 ($8,269-33,598) $18,676  $24,369 $10,119 ($5,401-$20,992) <.01 46.8
Renal impairment $32,552  $33,504 $20,565 ($10,644-$41,236) $22,329  $27,579 $12,529 ($6,408-$25,958) <.01 45.8
Neoplasm $33,246  $33,908 $20,934 ($10,773-$42,907) $23,579  $13,096 $12,868 ($7,174-$28,184) <.01 41.0
Immunocompromised $43,078  $41,102 $27,655 ($13,050-$59,987) $32,914  $37,001 $18,093 ($7,987-$44,244) <.01 30.9
Inﬂammatory bowel disease $27,387  $32,440 $14,787 ($7,089-$34,898) $14,334  $20,341 $7,720 ($4,541-$15,131) <.01 91.1
Concomitant antibiotic $33,072  $33,754 $20,954 ($10,897-$42,097) $22,484  $27,720 $12,461 ($6,430-$26,134) <.01 47.1
30-d all-cause readmission n % n %
Percentage-point
difference
All eligible 17,539 23.2 11,536 14.8 <.01 8.4
Renal impairment 8,415 25.0 4,718 16.6 <.01 8.4
Neoplasm 2,707 25.5 1,878 19.8 <.01 5.7
Immunocompromised 1,239 30.4 723 23.7 <.01 6.6
Inﬂammatory bowel disease 542 21.0 235 15.6 <.01 5.3
Concomitant antibiotic 11,305 23.3 7,066 14.8 <.01 8.5
CDAD, Clostridium difﬁcile-associated diarrhea; ICU, intensive care unit; IQ, interquartile; SNF, skilled nursing facility.
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increased LOS, total patient costs, and risk of readmission for
patients with CDAD.11 The increase in LOS with CDAD was 4.7 days,
and the total cost attributable was $7,286. These results are broadly
similar to those of Kyne et al8 (attributable LOS, 3.6 days; attrib-
utable cost, $3,669) and Song et al3 (attributable LOS, 5.5 days;
attributable cost, $6,326). Both of these studies were conducted
at single institutions, whereas the current study used recent,
geographically diverse data from several hundred hospitals, pre-
sumably providing a more generalizable estimate of current
conditions.
The subgroup analysis of vulnerable clinical populations with
known increased risk of infection suggested that the effect of CDAD
on the reported outcomes is consistent throughout the populations.
The effect of CDAD on inpatient mortality and readmission was
similar to the overall population analysis. In all subgroups, total
inpatient costs were higher for patients with CDAD than for con-
trols, conﬁrming previous ﬁndings.9,10,14,15 The CDAD-attributable
cost was slightly higher for patients with renal impairment
($8,942), immunocompromised status ($8,692), and concomitant
antibiotic exposure ($8,545), comparedwith the overall population.
Patients with CDAD had signiﬁcantly higher 30-day readmission
rates than controls in the overall population and in each high-risk
subgroup studied. Comparing all-cause readmission rates
observed here with previous studies is difﬁcult because of varyingdeﬁnitions used for identifying the CDAD population and differ-
ences in sample size, time periods, and deﬁnition of readmission.
Despite these potential confounding variables, the rates of read-
mission reported here are comparable with those found in recent
studies.7,11,16,17 Although we have not speciﬁcally focused on CDAD
recurrence, it is likely a contributor to the increased 30-day all-
cause readmission rates and should be considered by hospitals
for more accurate estimations of potential future costs. Indeed, a
recent study demonstrated that approximately 50% of patients with
recurrence were rehospitalized within 3 months.16 Moreover, it
seems that using the appropriate initial treatment for CDAD should
be a priority for preventing downstream resource utilization and
readmission, speciﬁcally in vulnerable patients.
This study adds to previous research in several ways particularly
important to acute care hospitals. First, it provides an analysis using
data from a large number of geographically diverse hospitals. Pre-
vious large-database analyses relied on Medicare data, the National
Hospital Discharge Survey, or state databases, whereas other cohort
studies relied on retrospective or prospective data from small
numbers of acute care facilities. Each approach limits the general-
izability of results. Second, we used an easily reproduced deﬁnition
of CDAD. Use of ICD-9 coding to identify CDAD cases has been
shown to have good concordance with cases identiﬁed by C difﬁcile
toxin assays.18 Inclusion of patients treated with ﬁdaxomicin,
metronidazole, or vancomycin helps identify individuals in an
Table 4
Adjusted outcomes of patients with CDAD versus patients without CDAD
Inpatient mortality Odds ratio Lower* Upper* P value
All eligible 1.13 1.09 1.17 <.01
Renal impairment 1.14 1.09 1.19 <.01
Neoplasm 1.06 0.98 1.15 .14
Immunocompromised 1.09 0.94 1.27 .26
Inﬂammatory bowel
disease
2.57 1.84 3.59 <.01
Concomitant antibiotic 1.13 1.08 1.18 <.01
Total length of stay, d CDAD Non-CDAD
Percentage
difference P value
All eligible 13.2 8.5 55.3 <.01
Renal impairment 14.5 9.4 54.3 <.01
Neoplasm 13.6 8.9 52.8 <.01
Immunocompromised 17.8 12.0 48.3 <.01
Inﬂammatory bowel
disease
10.4 6.9 50.7 <.01
Concomitant antibiotic 14.9 9.5 56.8 <.01
ICU length of stay, d CDAD Non-CDAD
Percentage
difference P value
All eligible 8.3 6.6 25.8 <.01
Renal impairment 10.3 8.5 21.2 <.01
Neoplasm 4.7 3.7 27.0 <.01
Immunocompromised 6.6 5.5 20.0 <.01
Inﬂammatory bowel
disease
7.8 6.1 27.9 <.01
Concomitant antibiotic 5.0 4.1 22.0 <.01
Total patient cost CDAD Non-CDAD
Percentage
difference P value
All eligible $25,804 $18,518 39.3 <.01
Renal impairment $31,263 $22,321 40.1 <.01
Neoplasm $24,694 $17,719 39.4 <.01
Immunocompromised $33,064 $24,372 35.7 <.01
Inﬂammatory bowel
disease
$19,667 $14,141 39.1 <.01
Concomitant antibiotic $29,581 $21,036 40.6 <.01
30-d all-cause
readmission Odds ratio Lower* Upper* P value
All eligible 1.77 1.73 1.82 <.01
Renal impairment 1.66 1.59 1.73 <.01
Neoplasm 1.45 1.36 1.56 <.01
Immunocompromised 1.45 1.30 1.62 <.01
Inﬂammatory bowel
disease
1.33 1.12 1.59 <.01
Concomitant antibiotic 1.70 1.64 1.76 <.01
60-d all-cause
readmission Odds ratio Lower* Upper* P value
All eligible 1.83 1.79 1.87 <.01
Renal impairment 1.71 1.65 1.77 <.01
Neoplasm 1.49 1.40 1.58 <.01
Immunocompromised 1.53 1.38 1.70 <.01
Inﬂammatory bowel
disease
1.41 1.21 1.65 <.01
Concomitant antibiotic 1.73 1.68 1.78 <.01
90-d all-cause
readmission Odds ratio Lower* Upper* P value
All eligible 1.83 1.79 1.87 <.01
Renal impairment 1.71 1.65 1.77 <.01
Neoplasm 1.48 1.39 1.57 <.01
Immunocompromised 1.58 1.43 1.75 <.01
Inﬂammatory bowel
disease
1.47 1.27 1.71 <.01
Concomitant antibiotic 1.73 1.68 1.78 <.01
CDAD, Clostridium difﬁcile-associated diarrhea; ICU, intensive care unit.
*95% conﬁdence interval of odds ratio.
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use patient-care costs reported directly from hospital charge-
masters, rather than billed charges or cost-to-charge ratios.
Our study has several limitations. First, the method for identi-
fying CDAD used only ICD-9-CM and antibiotic exposure data anddid not require a positive C difﬁcile toxin assay. Although the
concordance between the 2 is believed to be high, the size of the
CDAD population may have been overestimated. Second, our study
only considered hospital costs and not physician or treatment costs
beyond the index hospitalization. Therefore, our costs were not an
estimate of the total cost of CDAD to the health system. Third,
readmission rates were calculated based on readmission to the
same hospital. Admission to a different hospital and mortality
outside of the hospital would not have been identiﬁed by the
Premier database; therefore, readmission rates may have been
underestimated; however, as shown previously, most patients
return to the same hospital for continuing care.19 Because the CDAD
population had higher rates of discharge to SNFs, hospices, and
other acute care facilities, this limitation may have systematically
underestimated the CDAD-related readmission risk. Fourth, our risk
adjustment methods relied on patient data, including comorbid-
ities at the time of discharge. Previous studies have observed that
mortality associated with CDAD is usually associated with under-
lying disease.8,20 Because we were unable to adjust for disease
severity at admission, this should be considered when interpreting
inpatient mortality risk. Finally, it is unknown whether patients
acquired C difﬁcile in the community or the hospital; however, most
patients were admitted from home or a SNF.1 The impact of disease
origin on acute care LOS, hospital costs, and readmission in patients
with CDAD, overall and in high-risk subgroups, could be addressed
in future studies.
In summary, after adjustment for risk factors, patients with
CDAD had increased odds of inpatient mortality, longer total and
ICU LOS, increased total patient costs, and increased odds of 30-,
60- and 90-day all-cause readmission compared with patients
without CDAD, overall and in the analyzed high-risk subgroups.
These results emphasize the continuing burden CDAD imparts on
U.S. hospitals. Efforts focused on preventing initial CDAD episodes,
and targeted therapy to prevent recurrences for vulnerable
patients, are essential to decrease this burden.Acknowledgment
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